Prenatal diagnosis and 47,XXY

Area of Science:

• Prenatal Diagnosis
• Genetics
• Reproductive Health

Background:

• Prenatal genetic diagnosis has significantly advanced since the 1960s.
• Historically, invasive procedures like CVS and amniocentesis frequently detected 47,XXY.
• Current screening protocols, including maternal serum analytes and ultrasound, are not optimized for X-chromosome aneuploidies like 47,XXY.

Purpose of the Study:

• To review available methods for detecting 47,XXY during pregnancy.
• To evaluate the effectiveness of current screening and diagnostic techniques for 47,XXY.
• To discuss potential changes in detection rates with emerging technologies.

Main Methods:

• Review of traditional invasive prenatal diagnostic procedures (CVS, amniocentesis).
• Analysis of non-invasive screening methods: maternal serum analytes and fetal ultrasound (NT-screening).
• Consideration of cell-free fetal DNA (cfDNA) testing in maternal blood.

Main Results:

• Traditional invasive methods were effective but less common now due to screening protocols.
• Current screening methods (serum analytes, ultrasound) are not designed to detect 47,XXY.
• Cell-free fetal DNA screening may alter 47,XXY detection rates, depending on vendor reporting.
• Array comparative genomic hybridization (aCGH) offers higher resolution than karyotyping for microdeletions/duplications.

Conclusions:

• Current prenatal screening protocols may lead to missed diagnoses of 47,XXY.
• Increased detection of 47,XXY could occur with improved screening protocols and increased testing uptake.
• Advanced techniques like aCGH might make direct invasive testing more appealing for comprehensive genetic analysis.